Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
about
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'Application of IL-2 therapy to target T regulatory cell functionInsights into cytokine-receptor interactions from cytokine engineeringOptimal management of metastatic melanoma: current strategies and future directionsAdjuvants for peptide-based cancer vaccinesIL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expressionHeat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cellsThe allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Requirement of dual stimulation by homologous recombinant IL-2 and recombinant IL-12 for the in vitro production of interferon gamma by canine peripheral blood mononuclear cells.High-molecular-weight hyaluronan is a novel inhibitor of pulmonary vascular leakinessBeyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.Natural killer cell engineering for cellular therapy of cancerCo-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccinationAntibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms.Plasma angiopoietin 2 concentrations are related to impaired lung function and organ failure in a clinical cohort receiving high-dose interleukin 2 therapy.IL-2/α-IL-2 Complex Treatment Cannot Be Substituted for the Adoptive Transfer of Regulatory T cells to Promote Bone Marrow Engraftment.Effects of stimulating interleukin -2/anti- interleukin -2 antibody complexes on renal cell carcinoma.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).In vivo accumulation of T cells in response to IL-2/anti-IL-2 mAb complexes is dependent in part on the TNF family ligand 4-1BBL.Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.Multistage analysis of variants in the inflammation pathway and lung cancer risk in smokersT-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7RExpression, Identification and Characterize of CD25-Binding Epitope Modified Human IL-2 in Pichia pastoris.Role of IL-2 in cancer immunotherapyLimitations of IL-2 and rapamycin in immunotherapy of type 1 diabetesCytokines in cancer immunotherapy.Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Plasma concentrations of soluble IL-2 receptor α (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.The role of inflammation in the pathogenesis of lung cancer.Homeostatic maintenance of T cells and natural killer cells.
P2860
Q24301975-E4A22BFF-FE78-4F35-AC2E-7EF8C88E584DQ24632192-2F24E875-8206-4113-9957-EEA1C39BC722Q26827327-38818353-BED3-441D-B621-7D7E70CB5020Q26852703-E2196305-2530-4DF7-9086-F1C4DB315313Q26997338-789D1A61-EB0F-454F-B7C7-1EA50B3AD851Q28072236-04E737B3-776E-4AB9-98BD-9AB7538B9B0DQ28073154-B8F54790-2D20-47EC-854A-C7AD24931759Q28730751-FBEA7FC4-2CB0-4095-A7FF-444103CEE07DQ33585305-F6F7C627-2D31-4C08-BA43-DFB899ECC475Q33705698-69F493C1-49BA-4C5C-ABFF-E2ACB334F65DQ33724352-FBAA45A5-4CF9-4181-AE3D-D459C567925BQ33774512-1C71314F-1BBB-467D-BC13-F401A6A944E2Q33811204-12BBE359-91C2-4EA3-A7AB-54959C819776Q33945191-5B915409-D5D5-47AB-A564-D1169DBE74A1Q34305430-B1F2EB94-EF43-43FA-844D-D8A9CB9FBF75Q34901832-0BEA681F-B6D9-442B-96EB-D13E3F334203Q34982489-8CDE8BEA-E6A2-4492-9C59-B97EF9F1796FQ35556865-0D39835A-580B-4E30-80E8-99A6A9BEA9D7Q35600299-72575E9A-FA92-477E-AFCC-26E5C7F24B65Q35630914-0BE90A48-CF7A-4E17-9BC9-ABD5D886B088Q35742907-04A0F353-1F60-44CB-BFEC-5A6BC08003EEQ35885490-9111B2E0-9E36-46C2-9DFF-28B5F9C7485CQ35895478-D1BAB2AA-A29D-4410-A7A0-8473AF105232Q36024656-CFCE6E3E-7AF7-47F8-AB02-8D707111D076Q36153051-AF3CC0AB-9F3A-4104-9986-47324E8CC9EFQ36177023-9F23464A-6D4F-4E4F-ADE4-52D5393F7A90Q36367063-922DB9B6-1E7B-484B-9831-D27002111F8DQ36552580-72EC555F-876C-4BE4-A2B8-C3F9918C2E29Q36597510-1711B1D4-53B0-4305-A06B-D43B94D4336DQ36889720-B16EE294-151C-4871-9763-3380BCC87448Q36946354-6BDBBDE5-1DC2-446F-84BE-CE33BA635A5DQ37079072-9DFA27A3-03D1-496C-86E6-BC0E3D7C6004Q37110531-AF45CC81-BAAB-42DB-AC6D-1B721B2DF9F8Q37148152-B90EE408-8542-4FE1-B9B1-80E7D6BCB33DQ37194962-B25B0CF9-3C09-4811-A1C1-6B1E03EA26E2Q37281838-0B859B56-E2C0-4D49-96BC-651D94B9C944Q37471644-73665480-E893-4CC7-B633-5DFCAE0728F7Q37741534-1CC797B9-60E5-416E-9077-2A49EFC1F1F1Q37900640-19ADDF5E-C84E-4C19-B40F-FBB3ECD448E2Q37998380-23B0B4CF-6BFC-4114-B860-FCD07CADFA2E
P2860
Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@ast
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@en
type
label
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@ast
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@en
prefLabel
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@ast
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@en
P2860
P50
P356
P1476
Improved IL-2 immunotherapy by ...... phocytes and endothelial cells
@en
P2093
Sven Létourneau
P2860
P304
11906-11911
P356
10.1073/PNAS.1002569107
P407
P577
2010-06-14T00:00:00Z